Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chantix Faces FDA Safety Gauntlet After Pfizer Settles Product Liability Suits

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA advisory committees will discuss risk of serious neuropsychiatric adverse events with the smoking cessation drug at October meeting.

You may also be interested in...



Chantix Meta-Analyses Not Enough To Remove Boxed Warning, FDA Argues

Pfizer wants advisory committee to endorse several labeling changes for its smoking cessation drug, but FDA says decision should wait for post-marketing trial set to be completed in about a year.

Pfizer Litigation Strategy: Business Focus, Legal Alliance Drive Successes

Pfizer’s litigation department scored several key victories in the past year, which the company chalks up to its business approach to running cases and the teamwork of its law firms.

Chantix, Zyban Need Safety Studies In Patients With Mental Illness

FDA's mandate, part of a response to neuropsychiatric adverse events that also includes boxed warnings for the smoking-cessation drugs, follows a trend of requesting sicker patients in trials.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel